Late-Onset #AxSpA (lo-axSpA): A Distinct Subgroup? 👉rdcu.be/d9uzU 📊 Key findings from the Reuma-check cohort: ✔️ 28% of axSpA cases started at ≥45 years. ✔️ More common in females (51%) & psoriasis (42%). ✔️ Lower NSAID response (52%) & HLA-B27 positivity (32%). ✔️

Los esperamos en Septiembre San Vicente Fundación Asoreuma Facultad de Medicina | Universidad de Antioquia

Old therapies, new insights. Don’t miss Session 09 at #LUPUS2025— 💊 SLE treatment breakthroughs 📍24 May | 10:40–11:40 | Frontenac Ballroom With experts discussing hydroxychloroquine, belimumab, immunosuppressants & more. #LupusResearch #Rheumatology #SLE

Anti-synthetase syndrome (ASyS): Consensus on nomenclature and abbreviation for anti-synthetase syndrome is now done. Everyone should use this nomenclature and abbreviation for the ASyS going forward: an IMACS project academic.oup.com/rheumatology/a…

IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to

2024 ACR Lupus Nephritis Guidelines: The Controversies Drs. Maria Dall’Era & Michelle Petri discuss the sticking points in the latest lupus nephritis recommendations. 🗣️ Insightful, honest, and essential for your practice. 📍Full update on RheumNow: buff.ly/EFmVnVw

Treatment of erosive osteoarthritis #EULAR2025

Artrosis de manos ✋🤚erosiva: ✅ prednisona 10 mg/día, MTX 20 mg v.o/semanal, denosumab ❌ colchicina, hidroxicloroquina, MTX 10 mg v.o/semanal, antiTNF, antiIL1 #EULAR2025

"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymphoproliferative disorder of young adults- skin 2/3, sensorineural hearing loss, fever w/ endo & autoimmune dz. Best responses w IL6 inhib. #EULAR2025 Abst

Nerandomilast: the new & improved nintedanib. Does it work for our rheum pts? Autoimmune subgroup of FIBRONEER-ILD (NEJM last month) - mortality benefit vs placebo (this is new) - well tolerated (minimal increase in diarrhoea vs placebo) One to watch #EULAR2025 LB0003 Dr. John Cush

New EULAR Recommendations for the management of systemic lupus erythematosus with kidney involvement 2025... presented at #EULAR25 - Consideration for several aspects of patients health - Early combination therapy - Nephroprotective measures

Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis

CONGRESS | #EULAR2025 | PRESENTATION Laurent Arnaud, Laurent ARNAUD, Strasbourg University Hospitals, discussed the ERN ReCONNET-SLICC-SLEuro expert consensus on treating rare manifestations in #lupus. · 45 unique rare SLE manifestations have been identified; 21 were selected

SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENTS FOR LUPUS NEPHRITIS This systematic review and network meta-analysis doi.org/10.3899/jrheum… #LupusLupus #GLADEL #SLE #LES

The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis ⏩GPA and MPA ⏩ subglottic stenosis and ENT ⏩EGPA ⏩Service specifications ⏩Patient education and support. academic.oup.com/rheumatology/a…

Part of the special collection #Sjögren’s Syndrome: 👉rdcu.be/eLJnm 🧬Precision T2T strategies are emerging in Sjögren’s-linking clinical & molecular endotypes to tailored therapies 🔹B cell & IFN-driven subtypes 🔹Dynamic biomarker monitoring 🔹AI-assisted precision

🧩 C-ANCA positive + renal dysfunction + cavitating lung lesions = Wegener’s (Granulomatosis with Polyangiitis) Key clues: • C-ANCA → PR3 antibodies • Cavitary nodules on CXR → necrotizing granulomas • Renal involvement → pauci-immune GN 💡 Always rule out infection (esp.

🔥 GRAPPA: New Definitions for Difficult PsA • C2M-PsA: Ongoing symptoms after ≥1 b/tsDMARD, driven by complexity → comorbidities, chronic pain, obesity, fibromyalgia, mental health, access issues. • TR-PsA: True refractory inflammation → failure of ≥3 MoAs (≥2

IN RA: IgA-RF seen in 50%, IgA-ACPA in 20-40% (& are very specific). IgA-RF or -ACPA found in serum, saliva & syn.fluid.& may underlie "mucosal hypothesis" of RA. IgA-RF assoc w/ more severe RA, worse outcomes, Xtra-articular manifestations, & blunted TNF inhibitor responses

Clinical Characteristics and Evolution of Interstitial Lung Disease in Subtypes of Idiopathic Inflammatory Myositis With Prevalent Lung Manifestation: A Retrospective Analysis #Rheumatology #MedTwitter acrjournals.onlinelibrary.wiley.com/doi/10.1002/ac…